Anti-major histocompatibility complex class I-related chain A antibodies in organ transplantation

Transplantation Reviews

Volumn 22, Issue 1, 2008, Pages 27-38

  Morales Buenrostro, Luis Eduardo ^a   Alberú, Josefina ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CELL SURFACE PROTEIN; HLA B ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN A ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED CHAIN B ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ALLOIMMUNITY; ANTIBODY DETECTION; ANTIGEN RECOGNITION; ARTICLE; CARDIAC GRAFT REJECTION; CELL DESTRUCTION; CELL SPECIFICITY; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CHROMOSOME 6; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; DISEASE ASSOCIATION; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; KIDNEY GRAFT REJECTION; LYMPHOCYTE ACTIVATION; MULTIGENE FAMILY; NONHUMAN; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION;

ENDOTHELIAL CELLS; GENE EXPRESSION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; ISOANTIBODIES; LYMPHOCYTES; ORGAN TRANSPLANTATION;

EID: 36249024779     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trre.2007.09.006     Document Type: Article

References (112)

1. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 3 (2003) 665-673
2. Denton M.D., Magee C.C., and Sayegh M.H. Immunosuppressive strategies in transplantation. Lancet 353 (1999) 1083-1091
3. Morris P.J. Renal transplantation. In: Ginns L.C., Cosimi A.B., and Morris P.J. (Eds). Transplantation (1999), Blackwell Science, Malden, MA 285-311
4. Meier-Kriesche H.U., Schold J.D., and Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?. Am J Transplant 4 (2004) 1289-1295
5. Pascual M., Theruvath T., Kawai T., Tolkoff-Rubin N., and Cosimi A.B. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 346 (2002) 580-590
6. Nankivell B.J., and Chapman J.R. Chronic allograft nephropathy: current concepts and future directions. Transplantation 81 (2006) 643-654
7. Pei R., Lee J., Chen T., Rojo S., and Terasaki P.I. Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 60 (1999) 1293-1302
8. Wahrmann M., Exner M., Regele H., et al. Flow cytometry based detection of HLA alloantibody mediated classical complement activation. J Immunol Methods 275 (2003) 149-160
9. Pei R., Lee J.H., Shih N.J., Chen M., and Terasaki P.I. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75 (2003) 43-49
10. Martin L., Guignier F., Mousson C., Rageot D., Justrabo E., and Rifle G. Detection of donor-specific anti-HLA antibodies with flow cytometry in eluates and sera from renal transplant recipients with chronic allograft nephropathy. Transplantation 76 (2003) 395-400
11. Feucht H.E., Schneeberger H., Hillebrand G., et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 43 (1993) 1333-1338
12. Cerilli J., Brasile L., Galouzis T., Lempert N., and Clarke J. The vascular endothelial cell antigen system. Transplantation 39 (1985) 286-289
13. Ferry B.L., Welsh K.I., Dunn M.J., et al. Anti-cell surface endothelial antibodies in sera from cardiac and kidney transplant recipients: association with chronic rejection. Transpl Immunol 5 (1997) 17-24
14. Perrey C., Brenchley P.E., Johnson R.W., and Martin S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl Immunol 6 (1998) 101-106
15. Ball B., Mousson C., Ratignier C., Guignier F., Glotz D., and Rifle G. Antibodies to vascular endothelial cells in chronic rejection of renal allografts. Transplant Proc 32 (2000) 353-354
16. Gorer P.A. The detection of antigenic differences in mouse erythrocytes by the employment of immune sera. Br J Exp Pathol 17 (1936) 42-50
17. Snell G.D. Methods for the study of histocompatibility genes. J Genet 49 (1948) 7-103
18. Dausset J. Iso-leuco-anticorps. Acta Haematol 20 (1958) 156-166
19. Hakim N.S., and Papalois V.E. History of organ and cell transplantation (2003), Imperial Collage Press, Covent Garden (London)
20. Jeannet M., Pinn V.W., Flax M.H., Winn H.J., and Russell P.S. Humoral antibodies in renal allotransplantation in man. N Engl J Med 282 (1970) 111-117
21. Terasaki P.I., Kreisler M., and Mickey R.M. Presensitization and kidney transplant failures. Postgrad Med J 47 (1971) 89-100
22. Band M.R., Larson J.H., Rebeiz M., et al. An ordered comparative map of the cattle and human genomes. Genome Res 10 (2000) 1359-1368
23. Larson J.H., Rebeiz M.J., Stiening C.M., Windish R.L., Beever J.E., and Lewin H.A. MHC class I-like genes in cattle, MHCLA, with similarity to genes encoding NK cell stimulatory ligands. Immunogenetics 55 (2003) 16-22
24. Bahram S., Bresnahan M., Geraghty D.E., and Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 91 (1994) 6259-6263
25. Leelayuwat C., Hollingsworth P., Pummer S., et al. Antibody reactivity profiles following immunization with diverse peptides of the PERB11 (MIC) family. Clin Exp Immunol 106 (1996) 568-576
26. Hankey K.G., Drachenberg C.B., Papadimitriou J.C., et al. MIC expression in renal and pancreatic allografts. Transplantation 73 (2002) 304-306
27. Bahram S., and Spies T. Nucleotide sequence of a human MHC class I MICB cDNA. Immunogenetics 43 (1996) 230-233
28. Bahram S., Mizuki N., Inoko H., and Spies T. Nucleotide sequence of the human MHC class I MICA gene. Immunogenetics 44 (1996) 80-81
29. Fodil N., Laloux L., Wanner V., et al. Allelic repertoire of the human MHC class I MICA gene. Immunogenetics 44 (1996) 351-357
30. Bahram S., Shiina T., Oka A., Tamiya G., and Inoko H. Genomic structure of the human MHC class I MICB gene. Immunogenetics 45 (1996) 161-162
31. Bahram S., and Spies T. The MIC gene family. Res Immunol 147 (1996) 328-333
32. Bahram S. MIC genes: from genetics to biology. In: Dixon F.J. (Ed). Advances in immunology vol. 76 (2001), Academic Press, San Diego (Calif) 1-60
33. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A 93 (1996) 12445-12450
34. Collins R.W. Human MHC class I chain related (MIC) genes: their biological function and relevance to disease and transplantation. Eur J Immunogenet 31 (2004) 105-114
35. Zou Y., Han M., Wang Z., and Stastny P. MICA allele-level typing by sequence-based typing with computerized assignment of polymorphic sites and short tandem repeats within the transmembrane region. Hum Immunol 67 (2006) 145-151
36. Molinero L.L., Marcos C.Y., Mirbaha F., Fainboim L., Stastny P., and Zwirner N.W. Codominant expression of the polymorphic MICA alloantigens encoded by genes in the HLA region. Eur J Immunogenet 29 (2002) 315-319
37. Pellet P., Renaud M., Fodil N., et al. Allelic repertoire of the human MICB gene. Immunogenetics 46 (1997) 434-436
38. Fodil N., Pellet P., Laloux L., Hauptmann G., Theodorou I., and Bahram S. MICA haplotypic diversity. Immunogenetics 49 (1999) 557-560
39. Petersdorf E.W., Shuler K.B., Longton G.M., Spies T., and Hansen J.A. Population study of allelic diversity in the human MHC class I-related MIC-A gene. Immunogenetics 49 (1999) 605-612
40. Komatsu-Wakui M., Tokunaga K., Ishikawa Y., et al. MIC-A polymorphism in Japanese and a MIC-A-MIC-B null haplotype. Immunogenetics 49 (1999) 620-628
41. Tian W., Boggs D.A., Ding W.Z., Chen D.F., and Fraser P.A. MICA genetic polymorphism and linkage disequilibrium with HLA-B in 29 African-American families. Immunogenetics 53 (2001) 724-728
42. Zhang Y., Lazaro A.M., Zou Y., et al. MICA polymorphism in South American Indians. Immunogenetics 53 (2002) 900-906
43. Tian W., Boggs D.A., Uko G., et al. MICA, HLA-B haplotypic variation in five population groups of sub-Saharan African ancestry. Genes Immun 4 (2003) 500-505
44. Marin M.L., Savioli C.R., Yamamoto J.H., Kalil J., and Goldberg A.C. MICA polymorphism in a sample of the Sao Paulo population, Brazil. Eur J Immunogenet 31 (2004) 63-71
45. Piancatelli D., Del Beato T., Oumhani K., El Aouad R., and Adorno D. MICA polymorphism in a population from north Morocco, Metalsa Berbers, using sequence-based typing. Hum Immunol 66 (2005) 931-936
46. Gao X., Single R.M., Karacki P., Marti D., O'Brien S.J., and Carrington M. Diversity of MICA and linkage disequilibrium with HLA-B in two North American populations. Hum Immunol 67 (2006) 152-158
47. Rammensee H.G. Chemistry of peptides associated with MHC class I and class II molecules. Curr Opin Immunol 7 (1995) 85-96
48. Bevan M.J. Antigen presentation to cytotoxic T lymphocytes in vivo. J Exp Med 182 (1995) 639-641
49. Rudolph M.G., Stanfield R.L., and Wilson I.A. How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 24 (2006) 419-466
50. Romero P., Cerottini J.C., and Speiser D.E. The human T cell response to melanoma antigens. Adv Immunol 92 (2006) 187-224
51. Castellino F., and Germain R.N. Cooperation between CD4+ and CD8+ T cells: when, where, and how. Annu Rev Immunol 24 (2006) 519-540
52. Braud V.M., Allan D.S., and McMichael A.J. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 11 (1999) 100-108
53. O'Callaghan C.A., and Bell J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 163 (1998) 129-138
54. Braud V.M., Allan D.S., O'Callaghan C.A., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 391 (1998) 795-799
55. Lepin E.J., Bastin J.M., Allan D.S., et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 30 (2000) 3552-3561
56. Kovats S., Main E.K., Librach C., Stubblebine M., Fisher S.J., and DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
57. Favier B., LeMaoult J., and Carosella E.D. Functions of HLA-G in the immune system. Tissue Antigens 69 Suppl 1 (2007) 150-152
58. Ristich V., Zhang W., Liang S., and Horuzsko A. Mechanisms of prolongation of allograft survival by HLA-G/ILT4-modified dendritic cells. Hum Immunol 68 (2007) 264-271
59. Bacon L., Eagle R.A., Meyer M., Easom N., Young N.T., and Trowsdale J. Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173 (2004) 1078-1084
60. Pietrangelo A. The penetrance of hemochromatosis: mice to the rescue. Gastroenterology 132 (2007) 805-808
61. Kubin M., Cassiano L., Chalupny J., et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 31 (2001) 1428-1437
62. Ghetie V., and Ward E.S. Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Annu Rev Immunol 18 (2000) 739-766
63. Palming J., Gabrielsson B.G., Jennische E., et al. Plasma cells and Fc receptors in human adipose tissue: lipogenic and anti-inflammatory effects of immunoglobulins on adipocytes. Biochem Biophys Res Commun 343 (2006) 43-48
64. Ulu A., Gunal D., Tiras S., Egin Y., Deda G., and Akar N. EPCR gene A3 haplotype and elevated soluble endothelial protein C receptor (sEPCR) levels in Turkish pediatric stroke patients. Thromb Res 120 (2007) 47-52
65. Henshall S.M., Horvath L.G., Quinn D.I., et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst 98 (2006) 1420-1424
66. Dascher C.C., and Brenner M.B. CD1 antigen presentation and infectious disease. Contrib Microbiol 10 (2003) 164-182
67. Behar S.M., and Porcelli S.A. CD1-restricted T cells in host defense to infectious diseases. Curr Top Microbiol Immunol 314 (2007) 215-250
68. Kawachi I., Maldonado J., Strader C., and Gilfillan S. MR1-restricted V alpha 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J Immunol 176 (2006) 1618-1627
69. Bahram S., Inoko H., Shiina T., and Radosavljevic M. MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol 17 (2005) 505-509
70. Lanier L.L. NK cell recognition. Annu Rev Immunol 23 (2005) 225-274
71. Ehrlich L.I., Ogasawara K., Hamerman J.A., et al. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J Immunol 174 (2005) 1922-1931
72. Bauer S., Groh V., Wu J., et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285 (1999) 727-729
73. Meresse B., Chen Z., Ciszewski C., et al. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21 (2004) 357-366
74. Zhao J., Huang J., Chen H., Cui L., and He W. Vdelta1 T cell receptor binds specifically to MHC I chain related A: molecular and biochemical evidences. Biochem Biophys Res Commun 339 (2006) 232-240
75. Groh V., Rhinehart R., Randolph-Habecker J., Topp M.S., Riddell S.R., and Spies T. Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2 (2001) 255-260
76. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K.H., and Spies T. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96 (1999) 6879-6884
77. Wu J., Song Y., Bakker A.B., et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285 (1999) 730-732
78. Upshaw J.L., Arneson L.N., Schoon R.A., Dick C.J., Billadeau D.D., and Leibson P.J. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol 7 (2006) 524-532
79. Ogasawara K., Benjamin J., Takaki R., Phillips J.H., and Lanier L.L. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 6 (2005) 938-945
80. Zou Y., Mirbaha F., Lazaro A., Zhang Y., Lavingia B., and Stastny P. MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum Immunol 63 (2002) 30-39
81. Molinero L.L., Domaica C.I., Fuertes M.B., Girart M.V., Rossi L.E., and Zwirner N.W. Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum Immunol 67 (2006) 170-182
82. Zwirner N.W., Fernandez-Vina M.A., and Stastny P. MICA, a new polymorphic HLA-related antigen, is expressed mainly by keratinocytes, endothelial cells, and monocytes. Immunogenetics 47 (1998) 139-148
83. Zwirner N.W., Dole K., and Stastny P. Differential surface expression of MICA by endothelial cells, fibroblasts, keratinocytes, and monocytes. Hum Immunol 60 (1999) 323-330
84. Schrambach S., Ardizzone M., Leymarie V., Sibilia J., and Bahram S. In vivo expression pattern of MICA and MICB and its relevance to auto-immunity and cancer. PLoS ONE 2 (2007) e518
85. Radosavljevic M., and Bahram S. In vivo immunogenetics: from MIC to RAET1 loci. Immunogenetics 55 (2003) 1-9
86. Zhang Y., and Stastny P. MICA antigens stimulate T cell proliferation and cell-mediated cytotoxicity. Hum Immunol 67 (2006) 215-222
87. Zou Y., Heinemann F.M., Grosse-Wilde H., et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum Immunol 67 (2006) 230-237
88. Zwirner N.W., Marcos C.Y., Mirbaha F., Zou Y., and Stastny P. Identification of MICA as a new polymorphic alloantigen recognized by antibodies in sera of organ transplant recipients. Hum Immunol 61 (2000) 917-924
89. Le Bas-Bernardet S., Hourmant M., Coupel S., Bignon J.D., Soulillou J.P., and Charreau B. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 3 (2003) 167-177
90. Sumitran-Holgersson S., Wilczek H.E., Holgersson J., and Soderstrom K. Identification of the nonclassical HLA molecules, mica, as targets for humoral immunity associated with irreversible rejection of kidney allografts. Transplantation 74 (2002) 268-277
91. Mizutani K., Terasaki P., Rosen A., et al. Serial ten-year follow-up of HLA and MICA antibody production prior to kidney graft failure. Am J Transplant 5 (2005) 2265-2272
92. Terasaki P.I., Ozawa M., and Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 7 (2007) 408-415
93. Panigrahi A., Gupta N., Siddiqui J.A., et al. Post transplant development of MICA and anti-HLA antibodies is associated with acute rejection episodes and renal allograft loss. Hum Immunol 68 (2007) 362-367
94. Morales-Buenrostro L.E., Rodríguez-Romo R., de Leo C., et al. HLA and MICA antibodies: further evidence of their impact on graft loss two years after their detection. In: Terasaki P. (Ed). Clinical transplant 2006 (2007), Terasaki Foundation Laboratory, Los Angeles (Calif) 207-218
95. Suarez-Alvarez B., Lopez-Vazquez A., Diaz-Pena R., et al. Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome. Transpl Immunol 17 (2006) 43-46
96. Ozawa M., Terasaki P.I., Lee J.H., et al. 14th International HLA and Immunogenetics Workshop: report on the Prospective Chronic Rejection Project. Tissue Antigens 69 Suppl 1 (2007) 174-179
97. Seiler M., Brabcova I., Viklicky O., et al. Heightened expression of the cytotoxicity receptor NKG2D correlates with acute and chronic nephropathy after kidney transplantation. Am J Transplant 7 (2007) 423-433
98. Halloran P.F., Wadgymar A., Ritchie S., Falk J., Solez K., and Srinivasa N.S. The significance of the anti-class I antibody response. I. Clinical and pathologic features of anti-class I-mediated rejection. Transplantation 49 (1990) 85-91
99. Zhang Q., Liang L.W., Gjertson D.W., et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 79 (2005) 591-598
100. Karpinski M., Rush D., Jeffery J., et al. Flow cytometric crossmatching in primary renal transplant recipients with a negative anti-human globulin enhanced cytotoxicity crossmatch. J Am Soc Nephrol 12 (2001) 2807-2814
101. Crespo M., Pascual M., Tolkoff-Rubin N., et al. Acute humoral rejection in renal allograft recipients: I. Incidence, serology and clinical characteristics. Transplantation 71 (2001) 652-658
102. Amezaga N., Crespo M., Lopez-Cobos M., et al. Relevance of MICA antibodies in acute humoral rejection in renal transplant patients. Transpl Immunol 17 (2006) 39-42
103. Harris P.E., Bian H., and Reed E.F. Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis. J Immunol 159 (1997) 5697-5704
104. Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 74 (2002) 1192-1194
105. Suarez-Alvarez B., Lopez-Vazquez A., Gonzalez M.Z., et al. The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 7 (2007) 1842-1848
106. Suarez-Alvarez B., Lopez-Vazquez A., Diaz-Molina B., et al. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection. Transplantation 82 (2006) 354-361
107. Moll S., and Pascual M. Humoral rejection of organ allografts. Am J Transplant 5 (2005) 2611-2618
108. Akalin E., and Pascual M. Sensitization after kidney transplantation. Clin J Am Soc Nephrol 1 (2006) 433-440
109. Jordan S.C., Vo A.A., Peng A., Toyoda M., and Tyan D. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients. Am J Transplant 6 (2006) 459-466
110. Stegall M.D., Gloor J., Winters J.L., Moore S.B., and Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 6 (2006) 346-351
111. Montgomery R.A., Zachary A.A., Racusen L.C., et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 70 (2000) 887-895
112. Glotz D., Antoine C., Julia P., et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplant 2 (2002) 758-760